Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. (7th February 2022)

• Record Type: Journal Article
• Authors: Bilici, Ahmet; Uysal, Mukremin; Menekse, Serkan; Akin, Semih; Yildiz, Fatih; Turan, Merve; Sezgin Goksu, Sema; Beypinar, Ismail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Basaran, Gul; Olmez, Omer Fatih; Avci, Nilufer; Tural, Deniz; Sakin, Abdullah; Turker, Sema; Demir, Atakan; Temiz, Suleyman; Kaplan, Muhammed Ali; Dogan, Mutlu; Tanriverdi, Ozgur; Bilgetekin, Irem; Cinkir, Havva Yesil; Acikgoz, Ozgur; Paydas, Semra; Uslu, Ruchan; Turhal, Serdar
• Is Part Of: Cancer investigation. Volume 40:Number 2(2022)
• Page Start: 199
• Page End: 209
• Publication Date: 2022-02-07
• Subjects: Everolimus -- exemestane -- metastatic breast cancer -- hormone receptor-positive -- HER − negative -- efficacy; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2021.2017952
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Purpose: This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) metastatic breast cancer (MBC) patients in real-life settings. Methods: Overall, 204 HR+, HER2− MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results: The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response ( p = 0.035) and PFS ( p = 0.024). The presence of bone-only metastasis was associated with better treatment response ( p = 0.002), PFS ( p < 0.001), and OS ( p = 0.001). Conclusion: We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER − MBC patients.